John Cox (Credit: Repligen)
March 12, 2020 09:16 AM EDTUpdated 12:43 PM
Deals

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

Amber Tong

Soon af­ter John Cox took over as CEO at Torque Ther­a­peu­tics, he reached out to Jose‑Car­los Gutiér­rez‑Ramos.

Gutiér­rez‑Ramos, who left Syn­log­ic in 2018 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times